Viking Therapeutics (VKTX) Other Non-Current Liabilities (2015 - 2017)

Viking Therapeutics has disclosed Other Non-Current Liabilities across 3 years of filings, most recently posting $47113.0 for Q1 2017.

• Other Non-Current Liabilities for Q1 2017 came in at $47113.0, down 76.78% year-over-year; the trailing twelve-month figure through Mar 2017 was $47113.0 (down 76.78% YoY), and the FY2015 annual result was $183611.0, changed N/A from the prior year.
• Other Non-Current Liabilities came in at $47113.0 for Q1 2017 at Viking Therapeutics, down from $202882.0 in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $202882.0 in Q1 2016 to a low of $47113.0 in Q1 2017.
• The 3-year median for Other Non-Current Liabilities is $183611.0 (2015), against an average of $144535.3.
• Peak annual rise in Other Non-Current Liabilities reached 76.78% in 2017, while the deepest fall reached 76.78% in 2017.
• Viking Therapeutics' Other Non-Current Liabilities stood at $183611.0 in 2015, then gained by 10.5% to $202882.0 in 2016, then plunged by 76.78% to $47113.0 in 2017.
• The last three Other Non-Current Liabilities figures came in at $47113.0 (Q1 2017), $202882.0 (Q1 2016), and $183611.0 (Q4 2015), per Business Quant data.